Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

EMPEROR-Reduced trial committees and investigators

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial'. Together they form a unique fingerprint.

Medicine & Life Sciences